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while total costs incurred by this population sample were 3,774,256RSD. Highest 
unit utilization of services belongs to conservative dentistry (31.9%), oral surgery 
(19.5%) and radiology (17.4%), while highest value based turnover belongs to implan-
tology 90,765.33±43,012.31RSD, orthodontics 77,361.82±73,123.92RSD and pros-
thetics 60873.89±26788.87RSD. Most frequently treated diagnosis was tooth decay 
(33.8% unit services provided), pulpitis (11.2%) and impacted teeth (8.5%), while 
most expensive to treat were anomalies of tooth position (70,998.33±73122.73RSD), 
abnormalities of size and form of teeth (55,662.50±77,304.45RSD) and loss of teeth 
due to accident, extraction or local periodontal disease (36,835.35±37,128.28RSD). 
ConClusions: Although range of dental medical costs currently falls behind EU 
average, Serbia’s emerging economy is likely to expand in the long run while market 
demand for dental services will grow. Due to threatened financial sustainability of 
current health insurance patterns in Eastern Europe, getting acquainted with true 
size and structure of dental care costs might essentially support informed decision 
making in future.
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CoSt-EffECtivEnESS AnAlySiS of UStEkinUmAb ComPArEd With 
EtAnErCEPt for thE trEAtmEnt of modErAtE to SEvErE PSoriASiS in 
CoStA riCA
Obando C.A., Desanvicente-Celis Z., Herrera J.A., Moreira M., De Castro J.
Janssen, Panama, Panama
objeCtives: To assess the cost-effectiveness of Ustekinumab (UST) com-
pared with Etanercept (ETN) in Costa Rica, in patients with Moderate to Severe 
Psoriasis. Methods: A cohort simulation Markov Model was developed based on 
response rates for UST and ETN [Psoriasis Area Severity Index (PASI) ]. The time 
frame was 10 years. The perspective was that of the Public System of Health of 
Costa Rica. The health outcome of interest was Quality Adjusted Life Years (QALYs). 
Efficacy data was taken from the ACCEPT clinical trial; this phase III clinical trial 
directly compares UST and ETN, what strongly supports the efficacy data that is 
used in the model. Utilities for health states were taken from published studies. 
The base year was 2013. All costs are presented in Costa Rican currency (Colones – 
CRC). Costs and outcomes were discounted at 3.5%. Probabilistic sensitivity analysis 
(PSA) was conducted to assess uncertainty around the parameters. Results: UST 
resulted in 3.85 QALYs and ETN in 3.58, per patient, respectively. Mean total costs 
per patient were: CRC 8.441.031 for UST and CRC 5.401.222 for ETN. UST resulted 
both more costly and more effective than ETN. The Incremental Cost Effectiveness 
Ratio comparing UST and ETN was 11.142.470 per QALY Gained. According to the 
classification of the World Health Organization (WHO), the acceptable threshold for 
QALY Gained for Costa Rica is CRC 14.140.792 (3 times the Gross Domestic Product 
per capita). The results of the probabilistic sensitivity analysis showed that, at the 
threshold suggested by the WHO, the probability of UST of being cost effective, 
compared with ETN is around 70%. ConClusions: UST can be considered cost 
effective when compared to ETN, according to the threshold suggested by the WHO, 
in patients with moderate to severe Psoriasis, from the perspective of the Public 
System of Health of Costa Rica.
PSS23
CoSt-EffECtivEnESS of rAnibizUmAb on PAtiEntS With diffUSE 
diAbEtiC mACUlAr EdEmA Within thE PUbliC mExiCAn hEAlth CArE 
SyStEm
Ruiz Miranda C.I., Ubiarco Lopez V.
Novartis Mexico, Mexico, Mexico
objeCtives: To perform a cost-effectiveness analysis of Ranibizumab plus laser 
photocoagulation vs monotherapy with laser photocoagulation in patients with 
diffuse Diabetic Macular Edema (DME). Methods: A Markov model was designed 
to analyze laser Photocoagulation vs laser Photocoagulation plus Ranibizumab. 
Transition probabilities were obtained from RESTORE. The base patient was a dia-
betic with 53 years presenting DME, according to Mexican context. General mortality 
rates were elicited locally from CONAPO*. A panel Delphi was performed to get use 
of resources locally. The time horizon was 5, 7, and 10 (lifetime) years according 
to life expectancy from ENSANUT** 2013, discount rate 5%. The outcome was life 
years without visual impairment. The cost values were from Guidelines for the 
Exchange of Services in the Health Sector. Probabilistic sensitivity analysis (PSA) was 
performed using Monte Carlo technique. Results: Incremental Cost Effectiveness 
Ratios of the combination versus the monotherapy were: $5,019.57, $2,375.62 and 
$622.67 USD per life year without visual impairment in a time horizon of 5, 7 years 
and lifetime. Cost effectiveness curve showed Ranibizumab be a cost effective 
option at 98.7% vs monotherapy before reaching the GDP per capita. ConClusions: 
Ranibizumab demonstrated to be a more cost-effectiveness alternative than mono-
therapy with laser photocoagulation. These results show the possibility of achiev-
ing potential clinical benefit with Ranibizumab in patients suffering from loss of 
vision. *CONAPO National Council of Population **ENSANUT National Health and 
Nutrition Survey
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modElEd oUtComES And ovErAll CoStS of thE 13-vAlEnt 
PnEUmoCoCCAl ConjUgAtE vACCinE in thE tUniSiAn nAtionAl 
vACCinAtion ProgrAm
Zigmond J.1, Pecen L.1, Tichopad A.1, Roberts C.S.2, Jomaa I.3
1CEEOR s. r. o., Prague, Czech Republic, 2Pfizer Inc., New York, NY, USA, 3Pfizer Pharmaceuticals 
Tunisia, Tunis, Tunisia
objeCtives: Like other North African countries, Tunisia has a substantial burden of 
pneumococcal disease, with high resistance to antibiotics. The Tunisian population 
remains largely unprotected in the absence of a national immunization program 
(NIP). Methods: A decision-analytic model was developed to evaluate the potential 
outcomes and costs of the PCV13-based NIP compared to no vaccination. The model 
estimates bacteremia and meningitis (jointly IPD), all-cause community acquired 
pneumonia (CAP), and all-cause otitis media (OM). The demographics and disease 
and a higher percentage TBSA burned also corresponded to significantly higher 
costs. ConClusions: Mean total costs of burn care in the first three months post 
injury were estimated at € 24,246 and depended on age, etiology and TBSA. Mean 
total costs in our population probably apply for other high-income countries as well, 
although we should realize that patients with burn injuries are diverse and repre-
sent a broad range of total costs. To reduce costs of burn care, future intervention 
studies should focus on reducing length of stay and enabling an early return to work.
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thE CoSt of blindnESS in thE rEPUbliC of irElAnd 2010-2020
Green D.1, O Neill C.2, Ducorroy G.1, Skelly A.1, Keegan D.3, Kenny D.4, Naughton A.3,  
Keegan D.3
1Novartis Ireland, Dublin 4, Ireland, 2National University of Ireland, Galway, Galway, Ireland, 
3Mater Misericordiae Ubiversity Hospital, Dublin, Ireland, 4National Council for the Blind Ireland, 
Dublin, Ireland
objeCtives: Aims The aim of this study is to estimate the prevalence of blind-
ness in the Republic of Ireland and estimate the financial and economic cost of 
blindness between 2010 and 2020. Methods: The prevalence of blindness was 
based on the National Council for the Blind of Ireland blind register and adjusted 
for under registration found in previous literature. The financial cost of blind-
ness was based on the sum of total direct and indirect health care costs (direct 
health care costs due to blindness, cost of depression due to blindness, cost of 
injurious falls due to blindness) and non-health care costs (productivity losses, 
informal care and deadweight welfare loss). Where possible, methods adopted 
reflect those used elsewhere in the literature. Results: The total financial cost 
of blindness in the ROI is estimated to have been € 276. million in 2010. This is 
projected to increase by 32.6% to € 367 million in 2020 if current trends in disease 
burden continue. The total economic cost of blindness in the ROI is estimated to 
be € 809 million in 2010 and is predicted to increase to over € 1.1 billion in 2020 
based on current trends. ConClusions: A significant proportion of blindness 
can be avoided through the implementation of existing technologies by the 
health service. However a significant portion (98.04%) of the burden of illness 
falls beyond the health service (primarily to the Department of Social Protection 
and the Department of Finance) and may serve to reducethe priority of policies 
aimed at avoiding blindness that might otherwise be received.
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CoSt-of-illnESS StUdy of SEnilE CAtArACt in thE CzECh rEPUbliC
Kruntoradova I.1, Kruntorádová K.2, Rogalewicz V.2, Barták M.3
1Charles University, Kladno, Czech Republic, 2Czech Technical University in Prague, Kladno, Czech 
Republic, 3University of J.E.Purkyn? in Ústí nad Labem, Ústí nad Labem, Czech Republic
Cost-of-illness study of senile cataract in the Czech RepublicIlona Kruntorádová, 
Klára Kruntorádová, Vladimír Rogalewicz, Miroslav Barták. objeCtives: In the 
Czech Republic, 7% of patients with senile cataract are indicated for surgery each 
year, which means ten thousand of interventions annually. The aim of this study 
is to quantify direct costs in relation to the implanted intraocular lens type from 
both the public health insurance perspective and the patient’s perspective. The 
senile cataract surgery with monofocal IOL is covered by public health insur-
ance. Methods: Direct costs were calculated through a panel of experts that pro-
vided expert opinions, taking into account consumption of paid medical services 
provided to patients. The panel consisted of 6 experts (4 physicians from eye clinics, 
2 physicians from outpatient departments). Patient´s costs were obtained through 
a patient questionnaire asking the direct (out-of-pocket) expenses associated with 
the cataract. The study covered a cohort of 200 patients with senile cataract in 
non-productive age (65+). Data were collected from 4 clinics performing cataract 
surgery. Results: The structure of direct costs associated with senile cataract, 
its surgery, and treatment of possible complications has been specified. Direct 
costs of senile cataract surgery from the perspective of public health insurance 
are CZK24900 (»EUR907) per person. Patient´s direct costs are lower for monofocal 
lenses than for multifocal ones. Patients’ costs for an IOL and the related treatment 
reach up to CZK35000 (»EUR1275), out of pocket expenses after treatment average 
out at CZK4450 (»EUR162). ConClusions: Due to absence of laws governing medi-
cal care premium services and the age of patients, monofocal IOLs are implanted 
predominantly. As a consequence, up to CZK 30 million (»EUR 1 1 million) are saved 
on the public health insurance budget annually. Patients´ expenses for implanting 
multifocal lenses are offset by savings due to unrealized spending for eyeglasses 
and related medical care in the course of time.
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CoStS of dEntAl oUtPAtiEnt CArE – rESoUrCE USE diffErEntiAlS 
ACroSS CliniCAl dEntiStry brAnChES
Rancic J.1, Rancic N.2, Majstorovic N.3, Biocanin V.4, Milosavljevic M.4, Jakovljevic M.4
1Specialist Dentistry Clinic Dr D. Lopicic, Belgrade, Serbia and Montenegro, 2Military Medical 
Academy University of Defence Belgrade, Belgrade, Serbia and Montenegro, 3The Faculty of 
Dentistry University of Belgrade, Belgrade, Serbia and Montenegro, 4The Faculty of Medical 
Sciences University of Kragujevac, Kragujevac, Serbia and Montenegro
objeCtives: Dental medical care bears particular financial burden for Eastern 
European transitional economies due to its lack of insurance coverage in most 
countries of the region and almost complete out-of-pocket payments by citizens. 
This study estimates real costs of these services in the field and describe resource 
use patterns and differentials across clinical dentistry branches, ICD-10 diagnostic 
groups, and across particular medical services. Methods: In a case-series design 
prospective cost-comparison study has been conducted from the perspective of 
the patient. Sample size was 752 complete episodes of treatment, selected ran-
domly in 2012/2013 throughout an array of several specialist state-owned (university 
associated) and private-owned dental clinics in upper-middle income Serbia. All 
direct medical costs of dental care were taken into account. Costs were expressed 
in national currency Republican Serbian Dinar (RSD). Results: Mean total direct 
medical costs of dental care were 5,018.96±17,109.61RSD per single dentist visit 
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1Association of Dutch Burn Centres, Rotterdam, The Netherlands, 2Association of Dutch Burn 
Centres, Beverwijk, The Netherlands, 3Association of Dutch Burn Centres, Groningen, The 
Netherlands, 4VU University Medical Centre, Amsterdam, The Netherlands, 5Erasmus MC, 
Rotterdam, The Netherlands
objeCtives: In patients with burns an early accurate diagnosis of burn depth is 
essential to determine optimal treatment. The combination of Laser Doppler imaging 
(LDI) and clinical assessment leads to an accurate estimate of burn depth. However, 
the actual effects of the introduction of LDI on therapeutic decisions, clinical out-
comes and costs are unknown. The aim of our study was to analyse the effectiveness 
and cost-effectiveness of LDI in burn care. The effects of LDI on decision-making, 
clinical outcomes, costs, and cost-effectiveness were assessed. Methods: A ran-
domised controlled trial was conducted in all three Dutch burn centres, includ-
ing subsequent patients with burns of indeterminate depth. In the standard care 
(SC) group, burn depth and treatment choices were based on clinical assessment 
only, in the other group (LDI) clinical assessment and LDI results were combined. 
Primary outcome was the effect of the introduction of LDI on wound healing time. 
The economic evaluation was performed from a societal perspective with a bottom 
up approach, following the micro-costing method. Results: Mean time to wound 
healing from randomisation was 14.3 days in the LDI group and 15.5 days in the SC 
group (p= 0.258). In the subgroup of clinical patients requiring surgery earlier deci-
sion for surgery and a shorter wound healing time were observed in the LDI group 
(16.0 versus 19.9 days, p= 0.029). Mean total costs per patient were € 18 549 versus 
€ 18 896 (p= 0.837). ConClusions: LDI proved to provide guidance for therapeutic 
decisions with a significantly shorter wound healing time in the subgroup of clinical 
patients requiring surgery. When time to surgery can be reduced by 2.4 days, similar 
to the time to decision for surgery in our study, cost savings of € 794 per scanned 
patient can be achieved.
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CoSt-EffECtivEnESS AnAlySiS of ingEnolo mEbUtAto vErSUS miqUimod 
in thE trEAtmEnt of ACtiniC kErAtoSES in thE PErSPECtivE of thE 
itAliAn hEAlth SyStEm
Di Matteo S.1, Colombo G.L.2, Pellacani G.3, Bruno G.M.1
1S. A. V. E. Studi Analisi e Valutazioni economiche, Milan, Italy, 2University of Pavia, Milan, Italy, 
3Università degli Studi di Modena e Reggio Emilia, Modena, Italy
objeCtives: Actinic Keratosis (AK) is the most common neoplastic lesion of the 
skin, its prevalence in Italy is 1.4% in the adult population, over the age of 45 
years. The objective of this study is to evaluate through the development of a 
decision-tree model, the impact in terms of cost-effectiveness of treatment of 
patients with actinic keratosis (on the face), of ingenolo mebutato gel vs. imiqui-
mod cream. Methods: The effectiveness was expressed in terms of utility; the 
ratio of cost effectiveness was expressed in terms of cost per Quality Adjusted Life 
Years (QALYs). The time horizon of the simulation was 12 months. For ingenolo 
mebutato was considered the price to the public starting from the ex-factory price 
currently lower in Europe (Spain price), while for imiquimod has been adopted 
the reference price, because of the drug generication. It was also considered the 
adherence rate of patients to the two treatment alternatives, due to the different 
duration of treatment (2-3 days Vs. 4-8 weeks) and adverse events, which in the 
case of imiquimod may persist for all the therapy lenght. Results: Based on 
these assumptions, ingenolo mebutato therapy is found to be less expensive and 
more effective, and so dominant, compared to imiquimod. The cost-effectiveness 
analysis has been tested with univariate sensitivity analysis, which confirmed 
the validity of the base case. ConClusions: Based on these statement, it seems 
clear that ingenolo mebutato, due to its way of administration combined with its 
expected cost, represents a rational investment for the treatment of AK in the 
landscape of our national health system.
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CoSt-EffECtivEnESS of 13-vAlEnt vErSUS 10-vAlEnt PnEUmoCoCCAl 
ConjUgAtE vACCinE USE in CroAtiA nAtionAl vACCinAtion ProgrAm
Tichopad A.1, Pecen L.1, Roberts C.S.2, Uglesic L.3, Tesovic G.4, Rogier K.5
1CEEOR s. r. o., Prague, Czech Republic, 2Pfizer Inc., New York, NY, USA, 3Pfizer Croatia d. o. o., 
Zagreb, Croatia, 4University of Zagreb Medical School, Zagreb, Croatia, 5Pfizer bv, Capelle a/d 
IJssel, The Netherlands
objeCtives: The national immunization program (NIP) on a voluntary basis 
started in 2010 in Croatia, including the 10-valent PCV10 and the 13-valent PCV13. 
We compare the cost-effectiveness of PCV10 and PCV13 use in the NIP. Methods: 
A Markov model was developed to examine cost-effectiveness of PCV13 versus 
PCV10 from the payer’s perspective in 10 years. The simulated diseases were inva-
sive pneumococcal disease (bacteremia and meningitis), all-cause community 
acquired pneumonia (CAP), and all-cause acute otitis media (AOM). Direct effec-
tiveness was extrapolated from PCV7 clinical trials, adjusted by local serotype. 
Indirect effect (IE) was extrapolated from the US surveillance data following uni-
versal PCV7 use. Vaccine prices per dose for PCV10 and PCV13 were € 45.16 and 
€ 47.71, respectively. The epidemiology inputs were based on national sources or 
adopted from neighboring Slovenia. Costs were obtained from local reimburse-
ment lists and the DRG system. The IE for PCV10 was separately taken at 0%, 
50% and 100% level. Results: Compared to PCV10 with presumed no IE, PCV13 
could avoid additional 985 IPD cases, 15583 cases of inpatient and 26481 cases of 
outpatient CAP, and 53555 AOM cases, whereas for modeled 50% IE of PCV10 only 
679,10568,17 641 and 35026 cases would be avoided, and for modeled 100% IE of 
PCV10 372,5552,8798,16498 cases would be avoided, respectively. There would be 
2778 or 1958 or, 1137 deaths avoided, respectively. PCV13 compared to PCV10 with 
assumed no IE leads to € 3.060 million more spent on vaccination and € 28.585 mil-
lion saved, giving thus overall saving € 25.524 million in 10 years. ConClusions: 
The cost-effectiveness analysis showed PCV10 to be dominated by PCV13 by its 
overall lower costs and higher number of QALY as well as LYG gained, regard-
less of the IE level. The results were most sensitive to the cost and incidence of 
hospitalized pneumonia.
characteristics were obtained from WHO estimates or local sources, adjusted to 
local conditions. PCV13 direct and indirect effectiveness was extrapolated from 
PCV7 trials and surveillance records, adjusted to local serotype distribution. Cost 
of vaccine was USD 16.34. A discount rate for cost and life-years was 3%. The payer 
and societal perspectives were considered. Results: The budget impact in a sin-
gle year with PCV13-based NIP in place would amount to USD 1.82 million, or USD 
7.93 million without indirect vaccine protection considered. From this investment, 
141 971 illnesses (1071 IPDs, 12477 CAPs and 128423 OMs) and 347 deaths could be 
avoided annually. Without indirect vaccine protection, 58 524 illnesses (601 IPD, 4721 
CAP, 53202 OM) and 184 deaths could be avoided. The cost-effectiveness analysis 
produced ICER of USD 340/LYG or USD 367/QALY from the payer’s perspective. From 
the societal perspective, the NIP is dominant. Not considering indirect protection, 
the ICER would be USD 140/LYG or USD 152/QALY from a societal perspective and 
USD 1157/LYG or USD 1254/QALY from a payer perspective. ConClusions: PCV13-
based NIP delivers benefits and cost savings that greatly offset the investment into 
vaccine. WHO strongly encourages investment in interventions that deliver an addi-
tional year of life in full quality for less than one GDP per capita (USD 4237); hence, 
a PCV13-based NIP with the above ICER presents an attractive option.
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rAnibizUmAb for thE trEAtmEnt of viSUAl imPAirmEnt dUE to 
myoPiC ChoroidAl nEovASCUlArizAtion: CoSt-EffECtivEnESS vErSUS 
AflibErCEPt
Leteneux C.1, Haig J.2, Xue W.3, Bhattacharyya S.4
1Novartis Pharma AG, Basel, Switzerland, 2Optum, Burlington, ON, Canada, 3Optum, Uxbridge, 
UK, 4Novartis Healthcare Pvt. Ltd., Hyderabad, India
objeCtives: Ranibizumab has demonstrated efficacy in patients with myopic 
choroidal neovascularization (mCNV) and is the first anti-VEGF licensed in this 
indication. Aflibercept is being evaluated for use in mCNV. An existing model dem-
onstrating the cost-effectiveness of ranibizumab versus verteporfin photodynamic 
therapy was adapted to provide an initial evaluation of ranibizumab versus afliber-
cept. Methods: A Markov model in mCNV with a lifetime horizon and visual acuity 
health states was adapted to evaluate the cost-effectiveness of ranibizumab and 
aflibercept from a UK health care perspective. Baseline characteristics, injection 
frequency and ranibizumab efficacy were based on the disease activity treatment 
arm from the RADIANCE study (n= 116, Caucasian, Indian and East Asian patients). 
Data for aflibercept were derived from initial results for the aflibercept treatment 
arm from the MYRROR study (n= 90, East Asian patients only). Relative efficacy 
was assessed by indirect comparison. An evaluation using the East Asian subgroup 
of the ranibizumab disease activity treatment arm in RADIANCE (n= 35) was also 
conducted. Results: Ranibizumab dominated aflibercept in both evaluations. 
Based on the disease activity arm from RADIANCE, ranibizumab was associated 
with a lower lifetime cost (incremental cost -£1770) and higher lifetime quality-
adjusted life-years (QALYs) (incremental gain 0.02) than aflibercept. Results were 
similar for the evaluation based on the East Asian subgroup. Ranibizumab was 
associated with a lower lifetime cost (incremental cost -£2856) and higher lifetime 
QALYs (incremental gain 0.06) than aflibercept. These results were driven by the 
greater number of injections, higher treatment and recurrence costs, and smaller 
proportion of patients gaining ≥ 20 letters visual acuity for aflibercept compared 
with ranibizumab. ConClusions: This initial analysis suggests that ranibizumab 
is less costly and is associated with a gain in QALYs relative to aflibercept based on 
the disease activity arm and the East Asian subgroup from RADIANCE, as well as 
initial data from MYRROR.
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CoSt-EffECtivEnESS of AflibErCEPt in thE trEAtmEnt of mACUlAr 
oEdEmA SECondAry to CEntrAl rEtinAl vEin oCClUSion in SWEdEn
Eriksson M.1, Castelo-Branco A.2, Nilsson J.2
1Bayer AB, Solna, Sweden, 2OptumInsight, Stockholm, Sweden
objeCtives: Central retinal vein occlusion (CRVO) is caused by a blood clot in the 
central retinal vein, which slows or stops blood from leaving the retina. As a result, 
blood and fluids can accumulate, causing retinal injury and vision loss. Thus, a 
major complication in eyes with CRVO is macular oedema (ME) and is the primary 
factor for poor visual acuity and visual fields in non-ischemic CRVO. A global cost-
effectiveness model was developed and adopted to estimate effects and associ-
ated costs, in Sweden, for treatment of ME secondary to CRVO with aflibercept 
compared to ranibizumab. Methods: A Markov model was developed, including 
health states that reflect the clinical treatment and disease progression/regression 
of the ME. The simulated patient population consisted of adults treated for ME 
secondary to CRVO with an average starting-age of 64 years. Patients were treated 
and monitored for two years and followed for 15 years in the base case. Treatment 
regimens were taken from clinical trials with aflibercept (GALILEO & COPERNICUS) 
and ranibizumab (CRUISE & HORIZON), with 8.2 vs. 8.8 injections the first year and 
2.9 vs. 3.5 injections the second year, respectively. Results: Aflibercept can be 
regarded as a cost-effective, i. e. dominating, treatment-alternative compared to 
ranibizumab as aflibercept is both less costly (total incremental cost of more than 
-35,000 SEK) and more effective (total incremental QALYs of 0.061) than ranibi-
zumab. Due to the more treatments, ranibizumab had higher drug (incremental 
cost: -8,537 SEK) and administration (incremental cost: -5,793 SEK) costs compared 
to aflibercept. Probabilistic sensitivity analysis showed that aflibercept was domi-
nating over ranibizumab in 70% of the simulations. ConClusions: Aflibercept 
is more cost-effective than ranibizumab for the treatment of ME secondary to 
CRVO in Sweden.
PSS27
CoSt-EffECtivEnESS of lASEr doPPlEr imAging in bUrn CArE in thE 
nEthErlAndS; A rAndomiSEd ControllEd triAl
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